Fore Biotherapeutics Inc.

Fore Biotherapeutics Inc. is a biopharmaceutical company focused on developing innovative cancer therapies, particularly an investigational BRAF inhibitor aimed at addressing unmet medical needs in oncology. Founded in 2012, Fore Biotherapeutics Inc. is headquartered in Philadelphia, US.

The company specializes in advancing targeted cancer therapies and has successfully completed a total of 13 investment deals. Its latest funding round was a Series D in May 2025, raising USD 38. 00 mn from notable investors including SR One, Medicxi Ventures, and Novartis Venture Fund. The company's CEO is Matthew Ros.

Fore Biotherapeutics specializes in the development of innovative cancer therapies, centering its efforts on plixorafenib, an investigational next-generation BRAF inhibitor. This drug targets a broad spectrum of BRAF gene alterations in cancer cells, designed to enhance targeted therapy with a unique mechanism of action, allowing for single-agent activity and sustained tolerability. The company focuses on patients suffering from advanced, unresectable solid tumors with specific BRAF alterations, while also pursuing strategic global partnerships to expand its reach in precision oncology. Fore Biotherapeutics is in the investigational phase with its leading product, plixorafenib, which is not yet commercialized or approved for sale.

The company's revenue model is expected to rely on strategic partnerships and collaborations, particularly in-licensing clinic-ready compounds for rapid market development. Revenue generation will be contingent on successful trial outcomes and the establishment of licensing agreements structured around milestone payments and royalties from product sales. In May 2025, Fore Biotherapeutics Inc. raised USD 38.

00 mn in Series D funding to advance the FORTE Master Protocol. The company plans to use this investment for developing new products and expanding its presence in precision oncology, targeting strategic markets for future growth. Specific geographic regions for expansion have not been detailed, but the focus remains on enhancing its capabilities in oncology through additional partnerships and research initiatives.